Guardant Health, Inc. (GH) Stock

About Guardant Health, Inc.

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

Guardant Health, Inc. is led by CEO Helmy Eltoukhy, employs 2,506 people, headquartered in Palo Alto, US, publicly traded since 2018.

Guardant Health, Inc. (GH) stock trades at $145.13 with a market capitalization of $19.24B. The stock is valued at a price-to-earnings (P/E) ratio of -43.46, price-to-book of -106.81, price-to-sales of 18.09. Over the past 52 weeks the stock has ranged between $40.35 and $174.08, and currently trades 16.6% below its 52-week high.

On profitability, Guardant Health, Inc. generates a return on equity (ROE) of 184.27% — well above the market average, a sign of a high-quality business, return on capital employed of -27.57%, an operating margin of -41.43%, a net profit margin of -40.10%.

In its most recent fiscal year, Guardant Health, Inc. reported annual revenue of $982.0M, net profit of $-416.0M, revenue has compounded at 27.9% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of -9.41 — a conservative balance sheet with little leverage risk, a current ratio of 4.84, total assets of $2.0B, $378.0M in cash and equivalents.

GH has an average daily trading volume of 2,647,603 shares, a beta of 1.59 (more volatile than the overall market).

Official website: guardanthealth.com